TY - JOUR
T1 - Advancing Medical Applications of Cancer Nanotechnology
T2 - Highlighting Two Decades of the NCI'S Nanotechnology Characterization Laboratory Service to the Research Community
AU - Crist, Rachael M.
AU - Barenholz, Yechezkel
AU - Cern, Ahuva
AU - Clark, Kate N.
AU - Cullis, Pieter R.
AU - Dean, Cheryl
AU - Desai, Neil
AU - Ferrari, Mauro
AU - Germain, Matthieu
AU - Giacomantonio, Carmen A.
AU - Grabarnik, Emma
AU - Grodzinski, Piotr
AU - Hod, Atara
AU - Kennedy, Barry E.
AU - Kularatne, Ruvanthi N.
AU - Kwon, Glen S.
AU - Loeb, Emmanuel
AU - Noftall, Erin B.
AU - Pagliaro, Len
AU - Rasoulianboroujeni, Morteza
AU - Roth, Alexander
AU - Rowles, Darren
AU - Singh, Kulbir
AU - Steinmetz, Nicole F.
AU - Yehtina, Zhanna
AU - Zhang, Yao
AU - Zilbersheid, Daniel
AU - Clogston, Jeffrey D.
AU - Stern, Stephan T.
AU - Dobrovolskaia, Marina A.
N1 - Publisher Copyright: © 2025 The Author(s). WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals LLC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
PY - 2025/5/1
Y1 - 2025/5/1
N2 - The Nanotechnology Characterization Laboratory (NCL) is a US federally funded resource providing characterization and expertise to the cancer nanomedicine research community. Founded as a formal partnership among the US National Cancer Institute (NCI), the US Food and Drug Administration (FDA), and the US National Institute of Standards and Technology (NIST), the NCL has spent two decades developing a one-of-a-kind service with broad multidisciplinary expertise to meet the needs of a rapidly evolving drug development field. To mark the 20th anniversary of the lab's founding, the NCL hosted a symposium to highlight the achievements of the cancer nanomedicine field, showcase novel, next-generation nanotechnology research, and discuss future priorities to enable continued growth in combating cancer and the complexities associated with treating a disease that continues to take millions of lives annually. The discussion topics from this event are summarized.
AB - The Nanotechnology Characterization Laboratory (NCL) is a US federally funded resource providing characterization and expertise to the cancer nanomedicine research community. Founded as a formal partnership among the US National Cancer Institute (NCI), the US Food and Drug Administration (FDA), and the US National Institute of Standards and Technology (NIST), the NCL has spent two decades developing a one-of-a-kind service with broad multidisciplinary expertise to meet the needs of a rapidly evolving drug development field. To mark the 20th anniversary of the lab's founding, the NCL hosted a symposium to highlight the achievements of the cancer nanomedicine field, showcase novel, next-generation nanotechnology research, and discuss future priorities to enable continued growth in combating cancer and the complexities associated with treating a disease that continues to take millions of lives annually. The discussion topics from this event are summarized.
KW - cancer
KW - nanomedicine
KW - nanotechnology
UR - http://www.scopus.com/inward/record.url?scp=105007635386&partnerID=8YFLogxK
U2 - 10.1002/wnan.70020
DO - 10.1002/wnan.70020
M3 - مقالة
C2 - 40458962
SN - 1939-5116
VL - 17
JO - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
JF - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
IS - 3
M1 - e70020
ER -